233 related articles for article (PubMed ID: 33588869)
1. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
[TBL] [Abstract][Full Text] [Related]
2. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence.
Oblak T; Škerl P; Narang BJ; Blagus R; Krajc M; Novaković S; Žgajnar J
Breast; 2023 Dec; 72():103590. PubMed ID: 37857130
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
[TBL] [Abstract][Full Text] [Related]
5. Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.
Kurian AW; Hughes E; Simmons T; Bernhisel R; Probst B; Meek S; Caswell-Jin JL; John EM; Lanchbury JS; Slavin TP; Wagner S; Gutin A; Rohan TE; Shadyab AH; Manson JE; Lane D; Chlebowski RT; Stefanick ML
Cancer; 2021 Oct; 127(20):3742-3750. PubMed ID: 34228814
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
7. Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.
Hughes E; Tshiaba P; Wagner S; Judkins T; Rosenthal E; Roa B; Gallagher S; Meek S; Dalton K; Hedegard W; Adami CA; Grear DF; Domchek SM; Garber J; Lancaster JM; Weitzel JN; Kurian AW; Lanchbury JS; Gutin A; Robson ME
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036224
[TBL] [Abstract][Full Text] [Related]
8. Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density.
Brentnall AR; Cuzick J; Buist DSM; Bowles EJA
JAMA Oncol; 2018 Sep; 4(9):e180174. PubMed ID: 29621362
[TBL] [Abstract][Full Text] [Related]
9. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
Ghoncheh M; Ziaee F; Karami M; Poorolajal J
Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
[TBL] [Abstract][Full Text] [Related]
10. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.
Hurson AN; Pal Choudhury P; Gao C; Hüsing A; Eriksson M; Shi M; Jones ME; Evans DGR; Milne RL; Gaudet MM; Vachon CM; Chasman DI; Easton DF; Schmidt MK; Kraft P; Garcia-Closas M; Chatterjee N;
Int J Epidemiol; 2022 Jan; 50(6):1897-1911. PubMed ID: 34999890
[TBL] [Abstract][Full Text] [Related]
12. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort.
Brentnall AR; Harkness EF; Astley SM; Donnelly LS; Stavrinos P; Sampson S; Fox L; Sergeant JC; Harvie MN; Wilson M; Beetles U; Gadde S; Lim Y; Jain A; Bundred S; Barr N; Reece V; Howell A; Cuzick J; Evans DG
Breast Cancer Res; 2015 Dec; 17(1):147. PubMed ID: 26627479
[TBL] [Abstract][Full Text] [Related]
13. Polygenic risk scores for prediction of breast cancer in Korean women.
Jee YH; Ho WK; Park S; Easton DF; Teo SH; Jung KJ; Kraft P
Int J Epidemiol; 2023 Jun; 52(3):796-805. PubMed ID: 36343017
[TBL] [Abstract][Full Text] [Related]
14. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Lee A; Mavaddat N; Wilcox AN; Cunningham AP; Carver T; Hartley S; Babb de Villiers C; Izquierdo A; Simard J; Schmidt MK; Walter FM; Chatterjee N; Garcia-Closas M; Tischkowitz M; Pharoah P; Easton DF; Antoniou AC
Genet Med; 2019 Aug; 21(8):1708-1718. PubMed ID: 30643217
[TBL] [Abstract][Full Text] [Related]
15. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.
Lakeman IMM; Rodríguez-Girondo M; Lee A; Ruiter R; Stricker BH; Wijnant SRA; Kavousi M; Antoniou AC; Schmidt MK; Uitterlinden AG; van Rooij J; Devilee P
Genet Med; 2020 Nov; 22(11):1803-1811. PubMed ID: 32624571
[TBL] [Abstract][Full Text] [Related]
16. Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models.
Li SX; Milne RL; Nguyen-Dumont T; Wang X; English DR; Giles GG; Southey MC; Antoniou AC; Lee A; Li S; Winship I; Hopper JL; Terry MB; MacInnis RJ
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977228
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.
Boughey JC; Hartmann LC; Anderson SS; Degnim AC; Vierkant RA; Reynolds CA; Frost MH; Pankratz VS
J Clin Oncol; 2010 Aug; 28(22):3591-6. PubMed ID: 20606088
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
19. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
[TBL] [Abstract][Full Text] [Related]
20. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
